title: Lymphoma and immunosuppression: a report of a case associated with efalizumab therapy.
abstract: Lymphomas have been associated with immunodeficiency disorders, including those acquired secondary to the use of immunosuppressants for autoimmune disorders and for the prevention of graft rejection. Biologic agents have also been associated with the development of lymphoproliferative disorders. We report the case of Epstein-Barr Virus- negative diffuse large B-cell lymphoma associated with efalizumab, a monoclonal antibody that inhibits T-cell activity. Discontinuation of efalizumab resulted in a partial remission of lymphoma, although administration of chemotherapy was ultimately required. The use of immunomodulators must be tempered with the knowledge of their effect on the immune system and their association with lymphoproliferative disorders.
authors.affiliation: Baylor Sammons Cancer Center, Texas Oncology, PA, USA.
authors.forename: Pamela
authors.initials: P
authors.lastname: MacKenzie
authors.forename: Qurat-ul-Ain
authors.initials: QU
authors.lastname: Kamili
authors.forename: Alan
authors.initials: A
authors.lastname: Menter
authors.forename: Barry
authors.initials: B
authors.lastname: Cooper
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D040881:CD11a Antigen / Q000032:analysis; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D007108:Immune Tolerance; D007770:L-Lactate Dehydrogenase / Q000097:blood; D016403:Lymphoma, Large B-Cell, Diffuse / Q000139:chemically induced* / Q000276:immunology / Q000821:virology; D008297:Male; D008875:Middle Aged
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D040881:CD11a Antigen; D007770:L-Lactate Dehydrogenase; C472181:efalizumab